Snapshot: August Highlights
Executive Summary
A selection of articles you might have missed from August 2022, including a discussion on fake medicines and what's needed to tackle their existence, the die down of SPAC deals and how device-activated drugs may unlock new therapeutic avenues.
You may also be interested in...
Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers
An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.
Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023
Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.
Snapshot: January Highlights
A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.